{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:46:18Z","timestamp":1793126778609,"version":"4.5.0"},"reference-count":107,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.24124","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T15:01:12Z","timestamp":1631545272000},"page":"e2124124","source":"Crossref","is-referenced-by-count":59,"title":["Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease"],"prefix":"10.1001","volume":"4","author":[{"given":"Julie","family":"Martinkova","sequence":"first","affiliation":[{"name":"Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic"},{"name":"Women\u2019s Brain Project, Guntershausen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances-Catherine","family":"Quevenco","sequence":"additional","affiliation":[{"name":"Women\u2019s Brain Project, Guntershausen, Switzerland"},{"name":"Roche Diagnostics International Ltd, Rotkreuz, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Karcher","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Women\u2019s Brain Project, Guntershausen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Else Charlotte","family":"Sandset","sequence":"additional","affiliation":[{"name":"Stroke Unit, Department of Neurology, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Szoeke","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Hort","sequence":"additional","affiliation":[{"name":"Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic"},{"name":"International Clinical Research Center, St Anne\u2019s University Hospital Brno, Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Neurogeriatrics, University Clinic of Neurology, Medical University Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Santuccione","family":"Chadha","sequence":"additional","affiliation":[{"name":"Women\u2019s Brain Project, Guntershausen, Switzerland"},{"name":"Biogen International GMBH, Baar, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Ferretti","sequence":"additional","affiliation":[{"name":"Women\u2019s Brain Project, Guntershausen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"zoi210705r1","author":"?","year":"2015"},{"issue":"1","key":"zoi210705r2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","article-title":"Why has therapy development for dementia failed in the last two decades?","volume":"12","author":"Gauthier","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"2","key":"zoi210705r3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/brain\/aww353","article-title":"Alzheimer\u2019s disease: time to focus on the brain, not just molecules.","volume":"140","author":"Husain","year":"2017","journal-title":"Brain"},{"key":"zoi210705r5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer\u2019s disease facts and figures.","volume":"16","journal-title":"Alzheimers Dement"},{"issue":"8","key":"zoi210705r6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","article-title":"Sex differences in Alzheimer disease\u2014the gateway to precision medicine.","volume":"14","author":"Ferretti","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"zoi210705r7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/ene.v27.6","article-title":"Sex and gender differences in Alzheimer\u2019s disease: current challenges and implications for clinical practice: position paper of the Dementia and Cognitive Disorders Panel of the European Academy of Neurology.","volume":"27","author":"Ferretti","year":"2020","journal-title":"Eur J Neurol"},{"issue":"15","key":"zoi210705r8","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1212\/WNL.0000000000002570","article-title":"Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy.","volume":"86","author":"Sundermann","year":"2016","journal-title":"Neurology"},{"issue":"20","key":"zoi210705r9","doi-asserted-by":"crossref","first-page":"e1881","DOI":"10.1212\/WNL.0000000000008467","article-title":"Sex-specific norms for verbal memory tests may improve diagnostic accuracy of amnestic MCI.","volume":"93","author":"Sundermann","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"zoi210705r10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.trci.2015.07.001","article-title":"Marked gender differences in progression of mild cognitive impairment over 8 years.","volume":"1","author":"Lin","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"zoi210705r11","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1038\/s41598-018-25377-w","article-title":"Sex differences in cognitive decline in subjects with high likelihood of mild cognitive impairment due to Alzheimer\u2019s disease.","volume":"8","author":"Sohn","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"zoi210705r12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jalz.2018.04.010","article-title":"Sex, amyloid, and APOE e4 and risk of cognitive decline in preclinical Alzheimer\u2019s disease: findings from three well-characterized cohorts.","volume":"14","author":"Buckley","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"5","key":"zoi210705r13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamaneurol.2018.4693","article-title":"Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults.","volume":"76","author":"Buckley","year":"2019","journal-title":"JAMA Neurol"},{"issue":"5","key":"zoi210705r14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ana.v88.5","article-title":"Sex mediates relationships between regional tau pathology and cognitive decline.","volume":"88","author":"Buckley","year":"2020","journal-title":"Ann Neurol"},{"issue":"17","key":"zoi210705r15","doi-asserted-by":"publisher","first-page":"e2378","DOI":"10.1212\/WNL.0000000000010629","article-title":"Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE e4 genotype.","volume":"95","author":"Babapour Mofrad","year":"2020","journal-title":"Neurology"},{"issue":"8","key":"zoi210705r16","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1001\/jamaneurol.2018.0821","article-title":"Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau.","volume":"75","author":"Hohman","year":"2018","journal-title":"JAMA Neurol"},{"key":"zoi210705r17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.phrs.2016.11.035","article-title":"Sex and gender differences in the treatment of Alzheimer\u2019s disease: a systematic review of randomized controlled trials.","volume":"115","author":"Canevelli","year":"2017","journal-title":"Pharmacol Res"},{"key":"zoi210705r18","doi-asserted-by":"crossref","first-page":"i637","DOI":"10.1136\/bmj.i637","article-title":"Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers.","volume":"352","author":"Chen","year":"2016","journal-title":"BMJ"},{"issue":"7","key":"zoi210705r19","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1001\/jamaneurol.2018.0674","article-title":"Publication and dissemination of results in clinical trials of neurology.","volume":"75","author":"Sreekrishnan","year":"2018","journal-title":"JAMA Neurol"},{"issue":"9","key":"zoi210705r20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1177\/1747493019851292","article-title":"Trends in recruitment of women and reporting of sex differences in large-scale published randomized controlled trials in stroke.","volume":"14","author":"Carcel","year":"2019","journal-title":"Int J Stroke"},{"key":"zoi210705r21","first-page":"14898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"zoi210705r22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jneumeth.2016.10.005","article-title":"A comparison of methods for the analysis of binomial clustered outcomes in behavioral research.","volume":"274","author":"Ferrari","year":"2016","journal-title":"J Neurosci Methods"},{"issue":"7","key":"zoi210705r23","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1177\/0272989X14545789","article-title":"Use of generalized linear mixed models for network meta-analysis.","volume":"34","author":"Tu","year":"2014","journal-title":"Med Decis Making"},{"issue":"9634","key":"zoi210705r25","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled study.","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"issue":"21","key":"zoi210705r26","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1212\/01.wnl.0000335163.88054.e7","article-title":"Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.","volume":"71","author":"Sevigny","year":"2008","journal-title":"Neurology"},{"issue":"23","key":"zoi210705r27","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"zoi210705r28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/gps.2562","article-title":"SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study.","volume":"26","author":"Maher-Edwards","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"zoi210705r29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study.","volume":"30","author":"Gold","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"12","key":"zoi210705r30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"issue":"5","key":"zoi210705r31","doi-asserted-by":"publisher","first-page":"374","DOI":"10.2174\/156720510791383831","article-title":"Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer\u2019s disease.","volume":"7","author":"Maher-Edwards","year":"2010","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"zoi210705r32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease\u2014a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch Med Sci"},{"issue":"5","key":"zoi210705r33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2174\/156720511796391863","article-title":"Combination treatment in Alzheimer\u2019s disease: results of a randomized, controlled trial with cerebrolysin and donepezil.","volume":"8","author":"Alvarez","year":"2011","journal-title":"Curr Alzheimer Res"},{"issue":"13","key":"zoi210705r34","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease.","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"issue":"16","key":"zoi210705r35","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1212\/WNL.0b013e318216eb7b","article-title":"A phase II trial of huperzine A in mild to moderate Alzheimer disease.","volume":"76","author":"Rafii","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"zoi210705r36","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/156720511795256053","article-title":"EHT0202 in Alzheimer\u2019s disease: a 3-month, randomized, placebo-controlled, double-blind study.","volume":"8","author":"Vellas","year":"2011","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"zoi210705r37","doi-asserted-by":"publisher","first-page":"592","DOI":"10.2174\/156720511796391935","article-title":"Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer\u2019s disease: two phase 3 studies.","volume":"8","author":"Harrington","year":"2011","journal-title":"Curr Alzheimer Res"},{"issue":"11","key":"zoi210705r38","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the ?-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.","volume":"69","author":"Coric","year":"2012","journal-title":"Arch Neurol"},{"issue":"4","key":"zoi210705r39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2174\/156720512800492530","article-title":"Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.","volume":"9","author":"Egan","year":"2012","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"zoi210705r40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease.","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi210705r41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease.","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi210705r42","first-page":"S364","article-title":"Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer\u2019s disease.","volume":"10","author":"Marek","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"11","key":"zoi210705r43","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S1474-4422(14)70198-X","article-title":"Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer\u2019s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.","volume":"13","author":"Wilkinson","year":"2014","journal-title":"Lancet Neurol"},{"issue":"4","key":"zoi210705r44","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease.","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi210705r45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2174\/1567205010666131212110148","article-title":"A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer\u2019s disease.","volume":"11","author":"Grove","year":"2014","journal-title":"Curr Alzheimer Res"},{"issue":"17","key":"zoi210705r46","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1212\/WNL.0000000000000364","article-title":"Clinical trial of an inhibitor of RAGE-A\u00df interactions in Alzheimer disease.","volume":"82","author":"Galasko","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"zoi210705r47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.trci.2015.04.001","article-title":"Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer\u2019s disease.","volume":"1","author":"Maher-Edwards","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"zoi210705r48","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/WAD.0000000000000093","article-title":"Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease.","volume":"29","author":"Lenz","year":"2015","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"zoi210705r49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.trci.2015.06.001","article-title":"A phase 2 randomized, controlled trial of the a7 agonist ABT-126 in mild-to-moderate Alzheimer\u2019s dementia.","volume":"1","author":"Gault","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"zoi210705r50","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease.","volume":"44","author":"Wischik","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"zoi210705r51","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3233\/JAD-150414","article-title":"Effects of the acetylcholine release agent ST101 with donepezil in Alzheimer\u2019s disease: a randomized phase 2 study.","volume":"48","author":"Gauthier","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"zoi210705r52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.trci.2015.06.003","article-title":"A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer\u2019s disease.","volume":"1","author":"Maher-Edwards","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"issue":"4","key":"zoi210705r53","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3233\/JAD-150376","article-title":"Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-to-moderate Alzheimer\u2019s disease.","volume":"51","author":"Pasquier","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"10062","key":"zoi210705r54","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"zoi210705r55","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13195-016-0210-1","article-title":"ABT-126 monotherapy in mild-to-moderate Alzheimer\u2019s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.","volume":"8","author":"Gault","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"zoi210705r56","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.3233\/JAD-150978","article-title":"Efficacy and safety of ABT-126 in subjects with mild-to-moderate Alzheimer\u2019s disease on stable doses of acetylcholinesterase inhibitors: a randomized, double-blind, placebo-controlled study.","volume":"51","author":"Florian","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"zoi210705r57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","article-title":"Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials.","volume":"8","author":"Vandenberghe","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"zoi210705r58","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3233\/JAD-160369","article-title":"A phase II, randomized, double-blind, placebo-controlled study of safety, pharmacokinetics, and biomarker results of subcutaneous bapineuzumab in patients with mild to moderate Alzheimer\u2019s disease.","volume":"54","author":"Brody","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"zoi210705r59","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3233\/JAD-161309","article-title":"Sembragiline in moderate Alzheimer\u2019s disease: results of a randomized, double-blind, placebo-controlled phase II trial (MAyflOwer RoAD).","volume":"58","author":"Nave","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"18","key":"zoi210705r60","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1212\/WNL.0000000000003904","article-title":"A phase 3 trial of IV immunoglobulin for Alzheimer disease.","volume":"88","author":"Relkin","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"zoi210705r61","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/ageing\/afx045","article-title":"Efficacy and safety of a novel acetylcholinesterase inhibitor octohydroaminoacridine in mild-to-moderate Alzheimer\u2019s disease: a phase II multicenter randomised controlled trial.","volume":"46","author":"Xiao","year":"2017","journal-title":"Age Ageing"},{"issue":"1","key":"zoi210705r62","first-page":"1","article-title":"Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer\u2019s disease.","volume":"3","author":"Rinne","year":"2016","journal-title":"Alzheimers Dement (N Y)"},{"issue":"18","key":"zoi210705r63","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","article-title":"Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease.","volume":"378","author":"Egan","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi210705r64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002660","article-title":"Nilvadipine in mild to moderate Alzheimer disease: a randomised controlled trial.","volume":"15","author":"Lawlor","year":"2018","journal-title":"PLoS Med"},{"issue":"4","key":"zoi210705r65","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease.","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi210705r66","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: three randomized clinical trials.","volume":"319","author":"Atri","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"zoi210705r67","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13195-018-0368-9","article-title":"A phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer\u2019s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.","volume":"10","author":"Fullerton","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"zoi210705r68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","article-title":"Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer\u2019s disease.","volume":"4","author":"Voss","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"issue":"21","key":"zoi210705r69","doi-asserted-by":"publisher","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: a phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"issue":"11","key":"zoi210705r70","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jamaneurol.2019.1868","article-title":"Safety and efficacy of edonerpic maleate for patients with mild to moderate Alzheimer disease: a phase 2 randomized clinical trial.","volume":"76","author":"Schneider","year":"2019","journal-title":"JAMA Neurol"},{"issue":"10","key":"zoi210705r71","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1001\/jamaneurol.2019.2050","article-title":"Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: a randomized clinical trial.","volume":"76","author":"van Dyck","year":"2019","journal-title":"JAMA Neurol"},{"issue":"1","key":"zoi210705r72","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","article-title":"Safety and efficacy of galantamine (Reminyl) in severe Alzheimer\u2019s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.","volume":"8","author":"Burns","year":"2009","journal-title":"Lancet Neurol"},{"issue":"7","key":"zoi210705r73","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinthera.2010.06.019","article-title":"Effectiveness and tolerability of high-dose (23 mg\/d) versus standard-dose (10 mg\/d) donepezil in moderate to severe Alzheimer\u2019s disease: a 24-week, randomized, double-blind study.","volume":"32","author":"Farlow","year":"2010","journal-title":"Clin Ther"},{"issue":"1","key":"zoi210705r74","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000328929","article-title":"A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer\u2019s disease.","volume":"1","author":"Nakamura","year":"2011","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"5","key":"zoi210705r75","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000340056","article-title":"Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm2) in Alzheimer\u2019s disease.","volume":"33","author":"Cummings","year":"2012","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"6","key":"zoi210705r76","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-013-0077-7","article-title":"The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer\u2019s disease taking cholinesterase inhibitors.","volume":"27","author":"Grossberg","year":"2013","journal-title":"CNS Drugs"},{"key":"zoi210705r77","first-page":"391","article-title":"Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer\u2019s disease.","volume":"10","author":"Hager","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"3","key":"zoi210705r78","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000439269","article-title":"A 24-week, randomized, controlled study to evaluate the tolerability, safety and efficacy of 2 different titration schemes of the rivastigmine patch in Japanese patients with mild to moderate Alzheimer\u2019s disease.","volume":"5","author":"Nakamura","year":"2015","journal-title":"Dement Geriatr Cogn Dis Extra"},{"issue":"6","key":"zoi210705r79","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/cns.2016.22.issue-6","article-title":"Rivastigmine patch in Chinese patients with probable Alzheimer\u2019s disease: a 24-week, randomized, double-blind parallel-group study comparing rivastigmine patch (9.5 mg\/24 h) with capsule (6 mg twice daily).","volume":"22","author":"Zhang","year":"2016","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"zoi210705r80","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3233\/JAD-151149","article-title":"Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer\u2019s disease: a randomized, double-blind trial.","volume":"52","author":"Homma","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"zoi210705r81","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-019-0467-2","article-title":"Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer\u2019s disease.","volume":"11","author":"Fr\u00f6lich","year":"2019","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"zoi210705r82","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","article-title":"Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer\u2019s disease: results of a randomized, double-blind, placebo-controlled phase 2a study.","volume":"10","author":"Scheltens","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"7618","key":"zoi210705r83","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u00df plaques in Alzheimer\u2019s disease.","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"1","key":"zoi210705r84","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease.","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"zoi210705r85","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial.","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol"},{"issue":"15","key":"zoi210705r86","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized trial of verubecestat for prodromal Alzheimer\u2019s disease.","volume":"380","author":"Egan","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi210705r87","first-page":"276","article-title":"Additional results from a phase II study to assess the clinical and immunological activity, safety, and tolerability of AFFITOPE\u00ae AD02 in patients with early Alzheimer\u2019s disease (AD).","volume":"11","author":"Schneeberger","year":"2015","journal-title":"Alzheimers Dement"},{"issue":"1","key":"zoi210705r88","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.","volume":"69","author":"Craft","year":"2012","journal-title":"Arch Neurol"},{"issue":"3","key":"zoi210705r89","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/alzrt84","article-title":"Analyzing the impact of 23 mg\/day donepezil on language dysfunction in moderate to severe Alzheimer\u2019s disease.","volume":"3","author":"Ferris","year":"2011","journal-title":"Alzheimers Res Ther"},{"issue":"2-3","key":"zoi210705r90","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000338236","article-title":"Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer\u2019s disease: a subgroup analysis in patients already taking or not taking concomitant memantine.","volume":"33","author":"Doody","year":"2012","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"2","key":"zoi210705r91","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/15672050113106660167","article-title":"The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer\u2019s disease.","volume":"11","author":"Ohnishi","year":"2014","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"zoi210705r92","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13195-020-0580-2","article-title":"Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer\u2019s disease.","volume":"12","author":"Yoshida","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"zoi210705r93","first-page":"149","article-title":"Clinical effects of tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer\u2019s disease suggest disease modification potential.","volume":"4","author":"Abushakra","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"zoi210705r94","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/1533317512454708","article-title":"Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer\u2019s disease.","volume":"27","author":"Salloway","year":"2012","journal-title":"Am J Alzheimers Dis Other Demen"},{"issue":"10","key":"zoi210705r95","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/ijcp.12188","article-title":"Evaluation of an 8-item Severe Impairment Battery (SIB-8) vs. the full SIB in moderate to severe Alzheimer\u2019s disease patients participating in a donepezil study.","volume":"67","author":"Schmitt","year":"2013","journal-title":"Int J Clin Pract"},{"issue":"1","key":"zoi210705r96","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13195-016-0214-x","article-title":"Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer\u2019s disease: post-hoc analysis of a randomized placebo-controlled study.","volume":"8","author":"Hager","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"zoi210705r97","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-015-0121-6","article-title":"Peripheral and central effects of ?-secretase inhibition by semagacestat in Alzheimer\u2019s disease.","volume":"7","author":"Doody","year":"2015","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"zoi210705r98","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","article-title":"Amyloid-\u00df 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"issue":"3","key":"zoi210705r99","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.trci.2015.09.001","article-title":"Alzheimer\u2019s disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer\u2019s disease trials of bapineuzumab.","volume":"1","author":"Samtani","year":"2015","journal-title":"Alzheimers Dement (N Y)"},{"issue":"1","key":"zoi210705r100","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13195-014-0088-8","article-title":"Responder analysis of a randomized comparison of the 13.3 mg\/24 h and 9.5 mg\/24 h rivastigmine patch.","volume":"7","author":"Molinuevo","year":"2015","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"zoi210705r101","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/WAD.0000000000000261","article-title":"Memantine ER maintains patient response in moderate to severe Alzheimer\u2019s disease: post hoc analyses from a randomized, controlled, clinical trial of patients treated with cholinesterase inhibitors.","volume":"32","author":"Grossberg","year":"2018","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"10","key":"zoi210705r102","doi-asserted-by":"publisher","first-page":"e1912869","DOI":"10.1001\/jamanetworkopen.2019.12869","article-title":"Feasibility of using real-world data to replicate clinical trial evidence.","volume":"2","author":"Bartlett","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi210705r103","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial.","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol"},{"issue":"4","key":"zoi210705r105","doi-asserted-by":"publisher","first-page":"259","DOI":"10.18553\/jmcp.2002.8.4.259","article-title":"Neuroleptic drug exposure and incidence of tardive dyskinesia: a records-based case-control study.","volume":"8","author":"Marshall","year":"2002","journal-title":"J Manag Care Pharm"},{"key":"zoi210705r4","year":"2019"},{"key":"zoi210705r24","author":"R Core Team","year":"2020"},{"key":"zoi210705r104","author":"Boada","year":"2020"},{"key":"zoi210705r106"},{"key":"zoi210705r107"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2783983\/martinkova_2021_oi_210705_1630440429.31969.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T02:39:04Z","timestamp":1673231944000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2783983"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.24124","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]}}}